КУ Маннчинг Шерри (US),ЧЭНЬ Чих-куанг (TW),ЛУ Вэй-шу (TW),ЛИНЬ И-инь (TW)
申请号：
RU2013145498/15
公开号：
RU2013145498A
申请日:
2012.03.07
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A method of treating and / or preventing hyperuricemia or a metabolic disorder associated with hyperuricemia, comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from the group consisting of: 1) diacerein, 2) rhein and 3) their pharmaceutically acceptable salt, analogue, prodrug or active metabolite. 2. The method of claim 1, wherein said therapeutically effective amount of said compound is equivalent to 10-200 mg of diacerein base per day. The method of claim 1, wherein said active metabolite of diacerein is monoacetylrhein or rhein. The method according to claim 1, wherein said metabolic disorder associated with hyperuricemia is selected from the group consisting of acute gout, chronic gout, gouty arthritis, sudden exacerbation of gout, uric acid nephrolithiasis, and gouty nephropathy. The method of claim 1, wherein said method reduces uric acid level in the blood； and / or reduces the inflammatory effects of gouty arthritis and sudden exacerbations of gout caused by hyperuricemia； and / or dissolves kidney stones； and / or reduces the recurrence rate of acute inflammatory arthritis caused by hyperuricemia: and / or prevents recurrent hyperuricemia； and / or slows the progression of urate nephropathy in said patient. 6. The method of claim 1, wherein said method further comprises administering to said patient at least one additional therapeutic agent selected from the group consisting of anti-inflammatory agents and urate-lowering agents. A method that improves level control1. Способ лечения и/или предотвращения гиперурикемии или метаболического нарушения, связанного с гиперурикемией, включающий введение нуждающемуся в этом пациенту терапевтически эффективного количества соединения, выбранного из группы, состоящей из: 1) диацереина, 2) реина и 3) их фармацевтически приемлемой соли, аналога, пролекарства или активного метаболита.2. Способ по п. 1, в котором указанное терапевтически эффективное количеств
